

## CD30/TNFRSF8 Protein, Cynomolgus, Recombinant (His)

### General Information

Synonyms:	tumor necrosis factor receptor superfamily, member 8
Protein Construction:	Ala27-Pro394
Species:	Cynomolgus
Expression Host:	HEK293 Cells
Accession:	A0A2K5VW07
Molecular Weight:	39.86 kDa (predicted); 75-105 kDa (reducing condition, due to glycosylation)

### QC Testing

Biological Activity:	Immobilized Cynomolgus CD30, His Tag at 2 µg/ml (100 µl/Well) on the plate. Dose response curve for Anti-CD30 Antibody, hFc Tag with the EC50 of 6.0 ng/ml determined by ELISA (QC Test).
Purity:	> 95 % as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor (TNFR) superfamily. CD30 protein is expressed by activated, but not resting, T and B cells. CD30 can regulate proliferation of lymphocytes and may also play an important role in human immunodeficiency virus replication. As a regulator of apoptosis, CD30 protein induces cell death or proliferation, depending on the cell type, and has been shown to

limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. CD30 protein expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs), and CD30 is also linked to leukocytes in patients with chronic inflammatory diseases, including lupus erythematosus, asthma, rheumatoid arthritis and atopic dermatitis (AD). Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy

### Reference

- Rossi FM, et al. (2001) CD30L up-regulates CD30 and IL-4 expression by T cells. *FEBS Lett.* 508(3): 418-22.
- Trovato M, et al. (2001) Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules. *Thyroid.* 11(7): 621-8.
- Ekstrom ES, et al. (2001) Presence of CD30(+) and CD30L(+) cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy. *Placenta.* 22(4): 372-9.
- Tang C, et al. (2008) A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. *J Immunol.* 181(9): 6316-27.
- Sun X, et al. (2008) A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. *Gastroenterology.* 134(2): 447-58.
- Oflazoglu E, et al. (2009) Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases. *Adv Exp Med Biol.* 647: 174-85.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481